Abstract
Anti-inflammatory drugs consist of non-steroidal anti-inflammatory drugs (NSAIDs) including non-selective nsNSAIDs, aspirin, and cyclooxygenase-2 (COX-2)-selective inhibitors also referred to as coxibs, and glucocorticoids (GCs). They are worldwide prescribed drugs for many musculoskeletal conditions, such as osteoarthritis and inflammatory rheumatic diseases. Anti-inflammatory drugs can exert deleterious effects on the cardiovascular system, excluding aspirin. NSAIDs, especially coxibs, have been demonstrated to increase cardiovascular risk and have generated many concerns leading to the reassessment of their benefit/risk ratio. GCs may also induce cardiovascular events, but evidence seems to be less clear. Before prescribing these drugs, an assessment of cardiovascular risk may be judicious. In this review, anti-inflammatory drugs, coxibs, nsNSAIDs and GCs, and the risk of cardiovascular events will be discussed.
Keywords: Cardiovascular system, cardiovascular diseases, anti-inflammatory agents, NSAIDs, cyclooxygenase 2 inhibitors, glucocorticoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Volume: 12 Issue: 1
Author(s): Camille Roubille, Johanne Martel-Pelletier, Jean-Marc Davy, Boulos Haraoui and Jean-Pierre Pelletier
Affiliation:
Keywords: Cardiovascular system, cardiovascular diseases, anti-inflammatory agents, NSAIDs, cyclooxygenase 2 inhibitors, glucocorticoids
Abstract: Anti-inflammatory drugs consist of non-steroidal anti-inflammatory drugs (NSAIDs) including non-selective nsNSAIDs, aspirin, and cyclooxygenase-2 (COX-2)-selective inhibitors also referred to as coxibs, and glucocorticoids (GCs). They are worldwide prescribed drugs for many musculoskeletal conditions, such as osteoarthritis and inflammatory rheumatic diseases. Anti-inflammatory drugs can exert deleterious effects on the cardiovascular system, excluding aspirin. NSAIDs, especially coxibs, have been demonstrated to increase cardiovascular risk and have generated many concerns leading to the reassessment of their benefit/risk ratio. GCs may also induce cardiovascular events, but evidence seems to be less clear. Before prescribing these drugs, an assessment of cardiovascular risk may be judicious. In this review, anti-inflammatory drugs, coxibs, nsNSAIDs and GCs, and the risk of cardiovascular events will be discussed.
Export Options
About this article
Cite this article as:
Roubille Camille, Martel-Pelletier Johanne, Davy Jean-Marc, Haraoui Boulos and Pelletier Jean-Pierre, Cardiovascular Adverse Effects of Anti-Inflammatory Drugs, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (1) . https://dx.doi.org/10.2174/1871523011312010008
DOI https://dx.doi.org/10.2174/1871523011312010008 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews Recent Patents on Blueberry Picking
Recent Patents on Mechanical Engineering Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Measurements of Thermodynamic Acid Dissociation Constants for Three HMG-CoA Reductase Inhibitors by using RPLC and Study of Validation in Pharmaceutical Tablets
Current Pharmaceutical Analysis Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography
Current Radiopharmaceuticals Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss
Current Drug Therapy Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Anti-Inflammatory Responses of Resveratrol
Inflammation & Allergy - Drug Targets (Discontinued) STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – an Observational Study in Germany
Current Reviews in Clinical and Experimental Pharmacology Inhibition of Candida rugosa Lipase by Different Extracts of Five Algerian Plants and their Antioxidant Activities
Current Enzyme Inhibition Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets